Singapore-headquartered private equity major Everstone Capital on Tuesday announced the acquisition of a controlling stake in Calibre Chemicals, which is a specialty ingredients player focused on the pharmaceutical, nutritional and personal care segments, for a reported $100 million.
The city-based, privately-held Calibre was established in 1984 and manufactures a range of specialty chemicals falling into two product lines–mineral derivatives (iodine, selenium, cobalt) and peroxygens (persulphates, perchlorates). Though Everstone did not disclose deal value, sources told PTI it is around USD 100 million.
Calibre also offers various packaging solutions including paper cartons, HDPE drums, LDPE bags, steel drums, and fiber drums apart from manufacturing various custom chemicals at its Sarigam plant in Gujarat. It caters to several growing end industries like pharma, nutrition, and personal care and has customers in over 75 countries spanning the Americas, Europe, Africa, and Asia and nets two-thirds of its revenue from exports. It also has a wholly-owned subsidiary in Belgium.
Sameer Sain, co-founder, and chief executive of Everstone Group, said Calibre has a whole suite of specialty ingredient products with strong growth potential catering to both domestic and global markets. We believe our operational expertise and experience will help Calibre realize its global goals. Ranjit Bhavnani, founder-chairman and managing director of Calibre, said, the investment from Everstone endorses the growth trajectory that Calibre is on, and we aim to push the envelope with this investment.
Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.